SCHEMBL277376

SCHEMBL277376

Cc1cccc(NC(=O)CCC=O)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 2/20 0.64
HDAC1 Q13547 2/20 0.64
HDAC2 Q92769 2/20 0.64
HDAC10 Q969S8 2/20 0.64
HDAC11 Q96DB2 2/20 0.64
HDAC8 Q9BY41 2/20 0.64
HDAC6 Q9UBN7 2/20 0.64
HDAC4 P56524 1/20 0.64
HDAC7 Q8WUI4 1/20 0.64
HDAC9 Q9UKV0 1/20 0.64
HDAC5 Q9UQL6 1/20 0.64
NCOR2 Q9Y618 1/20 0.62
NPC1 O15118 1/20 0.59
POLB P06746 1/20 0.59
RAB9A P51151 1/20 0.59
MEN1 O00255 1/20 0.59
HPGD P15428 1/20 0.59
KMT2A Q03164 1/20 0.59
MAPT P10636 1/20 0.57
THRB P10828 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30544715 0.86 HDAC3 (0.62) HDAC3HDAC1HDAC2HDAC10HDAC11
SCHEMBL29054673 0.86 HDAC3 (0.62) HDAC3HDAC1HDAC2HDAC10HDAC11
SCHEMBL31611777 0.84 HDAC3 (0.68) HDAC3HDAC1HDAC2HDAC10HDAC11
SCHEMBL259380 0.84 HDAC3 (0.68) HDAC3HDAC1HDAC2HDAC10HDAC11
SCHEMBL13994594 0.82 HDAC3 (0.69) HDAC3HDAC1HDAC2HDAC10HDAC11
SCHEMBL14679379 0.82 HDAC3 (0.69) HDAC3HDAC1HDAC2HDAC10HDAC11
SCHEMBL2014002 0.81 MEN1 (0.72) HDAC3HDAC1HDAC2HDAC10HDAC11
SCHEMBL22743037 0.81 GAA (0.62) POLBMEN1HPGDKMT2AMAPT
SCHEMBL22868061 0.81 HDAC3 (0.68) HDAC3HDAC1HDAC2HDAC10HDAC11
SCHEMBL17376724 0.81 HDAC3 (0.68) HDAC3HDAC1HDAC2HDAC10HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A HDAC3 162/4885HDAC1 193/4885HDAC2 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.